Overview

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Status:
Active, not recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborator:

Foundation Medicine

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Gemcitabine
Paclitaxel
Rucaparib